deCODE biostuctures Extension of Contract with CGI Pharmaceuticals
News Jun 13, 2007
deCODE successfully solved the co-crystal structure of a human kinase (whose structure had not previously been reported) in complex with lead inhibitors developed by CGI Pharmaceuticals, Inc.
In addition, deCODE and CGI have now extended their X-ray crystallography collaboration to further support the ongoing drug development efforts at CGI.
“The high-resolution structural information provided by deCODE biostructures has provided a clear path for CGI to progress its structure-guided drug development programs. We are delighted to have now extended our collaboration with deCODE.” said David Armistead, Chief Scientific Officer of CGI.
“Under the extended agreement, deCODE biostructures is excited to continue supporting CGI through our gene to structure collaborative research on an exclusive kinase target.” remarked Lance Stewart, President of deCODE biostructures, Inc.
The research fee and milestone-based collaboration provides CGI with access to the expertise of deCODE biostructures in protein-ligand co-structure determination, from the engineering of synthetic kinase genes to the determination of high resolution kinase-ligand co-crystal structures. Financial details of the collaboration were not released.
Old age is the greatest risk factor for many diseases, including Alzheimer's disease (AD) and cancer. Geroprotectors are a recently identified class of anti-aging compounds. New research has now identified a unique subclass of these compounds, dubbed geroneuroprotectors (GNPs), which are AD drug candidates and slow the aging process in mice.READ MORE